Comparative Pharmacology
Head-to-head clinical analysis: KEFLET versus TAZICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFLET versus TAZICEF.
KEFLET vs TAZICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Keflet (warfarin) inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of clotting factors II, VII, IX, and X in the liver.
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3, leading to cell lysis and death.
500 mg orally every 12 hours for 10-14 days; for uncomplicated UTI: 250 mg orally every 12 hours for 7 days.
2 g intravenously every 8 hours for serious infections; 1 g intravenously every 8 hours for uncomplicated infections.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 20-30 hours in ESRD).
2 hours (prolonged to 4-12 hours in renal impairment; anuria: 20-30 hours).
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic